glp 1 agonist mechanism of action weight loss GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes GLP-1 Therapy Part 1: Setting

Medium-chain triglycerides (MCTs) consisting of decanoate (C10:0) can improve glucose tolerance and inhibit HFD-induced obesity in mice by stimulating GLP-1 secretion through GPR84 [148]

Rather than conducting a new meta-analysis, the authors synthesize findings from major randomized clinical trials, highlighting outcomes related to glycated hemoglobin (HbA1c), body weight reduction, major adverse cardiovascular events (MACE), and kidney function decline as reported in large cardiovascular outcomes trials (CVOTs), obesity randomized controlled trials, and early-phase clinical development studies

Retatrutide is not yet FDA-approved, so direct comparison in real-world use is not yet possible

This feature led to attempts to develop drugs that mimic GLP-1 for diabetes

Semaglutide & Tirzepatide is most effective when combined with healthy lifestyle changes, including diet and exercise